Women’s healthcare company Wisp has launched a diagnostics arm to offer low-cost testing at home for sexual and reproductive health, the company announced May 28.
Wisp is an online platform that prescribes medication for a range of women’s health needs such as oral contraception, yeast infections, fertility, emergency contraception and some medication abortion. Women can pick up their prescriptions at the pharmacy on the same day as their request, following approval by a provider. Wisp also ships medications in discreet packaging.
Wisp will now offer at-home tests for common sexually transmitted infections and free telehealth consultations for positive results, according to a release by the company. Patients will send completed urine tests or swabs to a partnered CLIA/CAP accredited laboratory and receive results in three to five business days.
The new model expands on Wisp’s direct-to-consumer telehealth platform and eliminates the need for patients to visit an in-person clinic to complete diagnostic testing. Patients can collect samples at home with tests sent in discreet packaging to maintain privacy in their healthcare and receive services entirely from home.
“Integrating diagnostics into Wisp’s already comprehensive care offerings was a natural evolution for the company,” Monica Cepak, Wisp CEO, said in a statement. “We’re simplifying the path to complete, 360-degree care—making it possible for patients to access testing and treatment from the comfort of home. Our mission has and continues to center around improving accessibility and affordability, which is why our testing kits are at the lowest price point on the market and include a free consultation to ensure every patient receives follow-up care.”
The Common STI test (Chlamydia, Gonorrhea, and Trichomoniasis) will cost $99, the 3-Site Panel (testing for Chlamydia and Gonorrhea) will cost $149 and the M-Gen Panel (testing for Mycoplasma Genitalium or Mgen) will cost $125, Wisp told Fierce Healthcare in an email. Wisp does not accept insurance.
The company plans to add more types of diagnostic tests to consumers in the coming months, including at-home testing kits focused on hormonal health later this year and in-home blood draw services to expand its fertility and menopause service lines.
“At Wisp, we’re committed to breaking down barriers in women’s healthcare. As providers, we see firsthand how access to reliable, discreet diagnostics—paired with fast, evidence-based treatment—can truly change lives,” Jillian LoPiano, M.D., Wisp's chief health officer, said in a statement. "By partnering with labs that meet the highest clinical standards for accuracy, and offering streamlined access to treatment when it’s needed, we’re not just improving convenience—we’re helping to destigmatize sexual health and empower patients to take control of their care with confidence.”
The Wisp platform has grown significantly in the last year by expanding into new categories like providing GLP-1s and nutrition counseling for weight loss and offering treatment for menopause. Cepak said the addition of the new service lines has been in direct response to consumer demand for the services.
“Our strategy has always been listening to our patients,” Cepak wrote in an email to Fierce Healthcare. “The expansion into areas like nutrition counseling, weight loss, and menopause care were in direct response to our patients requesting care options in these categories. We’ve built the largest platform for sexual and reproductive health, and expanding our offerings allows us to deepen patient trust by addressing more of the day-to-day health concerns our patients face.”